Cannabis Use Disorder Treatment Preferences: A Pilot Survey in Current Users of Cannabis

被引:0
|
作者
Lile, Joshua A. [1 ,2 ,3 ,7 ]
Turner, Brian W. [4 ]
Cox, David H. [1 ]
Bonn-Miller, Marcel O. [5 ]
Katz, Ned R. [1 ]
Shellenberg, Thomas P. [1 ]
Stoops, William W. [1 ,2 ,3 ]
Strickland, Justin C. [6 ]
机构
[1] Univ Kentucky, Coll Med, Dept Behav Sci, Lexington, KY USA
[2] Univ Kentucky, Coll Arts & Sci, Dept Psychol, Lexington, KY USA
[3] Univ Kentucky, Coll Med, Dept Psychiat, Lexington, KY USA
[4] Univ Kentucky, Coll Publ Hlth, Ctr Innovat Populat Hlth, Lexington, KY USA
[5] Canopy Growth Corp, Smiths Falls, ON, Canada
[6] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA
[7] Univ Kentucky, Coll Med, Dept Behav Sci, Lexington, KY 40536 USA
关键词
marijuana; pharmacotherapy; medication; behavioral therapy; psychosocial; adherence; NONRANDOM ASSIGNMENT; MEDICATIONS; INPATIENT; BARRIERS;
D O I
10.1097/ADM.0000000000001059
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
ObjectivesHighly effective treatments for cannabis use disorder (CUD) are lacking, and patient preferences have not been considered during treatment development. We therefore conducted an exploratory crowdsourced survey of individuals reporting current cannabis use and a willingness to cut down or quit their cannabis use, to determine their interest in various treatment aspects.MethodsSubjects (n = 63) were queried about their willingness to take medications as a function of type, route, and regimen and to participate in adherence monitoring. Subjects were also asked about their willingness to engage in behavioral/psychosocial interventions as a function of type, setting, and duration. Measures theorized to be associated with treatment preferences were also collected, including cannabis use variables, readiness to change, reduction or cessation goal, perceived cessation barriers, and medication use beliefs and behaviors.ResultsSurvey responses indicated that efforts to develop CUD medications should focus on nonsynthetic compounds administered orally or by mouth spray no more than once per day to maximize patient acceptance. Remote adherence monitoring and one-on-one outpatient behavioral treatment approaches, especially contingency management, are also anticipated to enhance participation. Most subjects indicated a preference to reduce their cannabis use rather than quit.ConclusionsThese data provide guidance for the development of CUD interventions based on the preferences of individuals interested in treatment for their cannabis use. Additional research is needed to confirm these results in a larger sample and determine if matching CUD patients with their preferred treatments improves success rates.
引用
收藏
页码:E87 / E93
页数:7
相关论文
共 50 条
  • [31] Contingency Management for Cannabis Use Disorder Treatment
    Lima, Marcelo G.
    Tardelli, Vitor S.
    Fidalgo, Thiago M.
    EUROPEAN ADDICTION RESEARCH, 2024, 30 (05)
  • [32] Emerging pharmacotherapy for the treatment of cannabis use disorder
    Shamabadi, Ahmad
    Bahri, Razman Arabzadeh
    Karimi, Hanie
    Heidari, Ehsan
    Akhondzadeh, Shahin
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (06) : 695 - 703
  • [33] PSYCHOPHARMACOLOGICAL TREATMENT OF ADOLESCENTS WITH CANNABIS USE DISORDER
    Hammond, Christopher Joseph
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2021, 60 (10): : S123 - S124
  • [34] Cannabis use preferences in women with myofascial pelvic pain: A survey
    Yang, E. C.
    Koenig, N. A.
    Gong, M.
    Brotto, L. A.
    Barr, A. M.
    Lee, T.
    Yong, P. J.
    Geoffrion, R.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2022, 33 (SUPPL 1) : S148 - S149
  • [35] Screening Medications for the Treatment of Cannabis Use Disorder
    Panlilio, L. V.
    Justinova, Z.
    Trigo, J. M.
    Le Foll, B.
    ANIMAL MODELS FOR MEDICATIONS SCREENING TO TREAT ADDICTION, 2016, 126 : 87 - 120
  • [36] Cannabis legislation and substance use disorder treatment
    Schwartz, Maria K. D.
    Connery, Hilary
    AMERICAN JOURNAL ON ADDICTIONS, 2019, 28 (02): : 127 - 129
  • [37] Sex differences in endocannabinoid tone in a pilot study of cannabis use disorder and acute cannabis abstinence
    Martin, Erin L.
    Baker, Nathaniel L.
    Sempio, Cristina
    Christians, Uwe
    Klawitter, Jost
    McRae-Clark, Aimee L.
    ADDICTION BIOLOGY, 2023, 28 (10)
  • [38] Pharmacotherapy for the Treatment of Cannabis Use Disorder RESPONSE
    Kansagara, Devan
    Kondo, Karli K.
    Morasco, Benjamin J.
    Nugent, Shannon M.
    Ayers, Chelsea K.
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (03) : 248 - 249
  • [39] Exercise as an adjunctive treatment for cannabis use disorder
    Brellenthin, Angelique G.
    Koltyn, Kelli F.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2016, 42 (05): : 481 - 489
  • [40] Mesocorticolimbic Activation is Associated With Abstinence From Cannabis in a Pilot Trial of Varenicline for Cannabis Use Disorder
    Martin, Erin
    Upton, Spencer
    Nowling, Briar
    Froeliger, Brett
    Squeglia, Lindsay
    Gray, Kevin
    McRae-Clark, Aimee
    DRUG AND ALCOHOL DEPENDENCE, 2025, 267